drugset / Trial / NCT00649714

Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg

NCT00649714

Phase 1 Completed 110 enrolled Mylan Pharmaceuticals Inc
RandomizedParallel-groupOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan's zonisamide, 100 mg capsules to Elan's Zonegran® 100 mg capsules following a single, oral 100 mg (1 x 100 mg) dose administered under fed conditions.

Timeline

Start
2003-12
Primary completion
2004-01
Completion
2004-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zonisamide Other / unclassified 100 mg Oral

Indications

No indication recorded.